17
total announcements
IOLCP.NS · 15 min delayed
IOL Chemicals and Pharmaceuticals Limited
IOL Chemicals and Pharmaceuticals Limited has informed the Exchange about a scheduled analyst/institutional investor meeting on 3rd September 2026, where the management will discuss past financial results and publicly available information.
IOL Chemicals and Pharmaceuticals Limited
IOL Chemicals and Pharmaceuticals Limited has announced its Q1 FY27 earnings conference call transcript, highlighting a strong start to the financial year with healthy demand across key products, improved capacity utilization, and favorable product mix. The company has made progress in diversifying its API portfolio beyond ibuprofen, with non-ibu products contributing 43% of pharmaceutical revenue in Q1 FY27, up from 36% in Q1 FY26.
IOL Chemicals and Pharmaceuticals Limited
IOL Chemicals and Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication regarding Special Window for Transfer-cum-Dematerialisation of Physical Securities.
IOL Chemicals and Pharmaceuticals Limited
IOL Chemicals and Pharmaceuticals Limited has made available the audio recording of its analysts/investors call regarding its Q1 FY2027 financial results.
IOL Chemicals and Pharmaceuticals Limited
IOL Chemicals and Pharmaceuticals Limited has released its Q1 FY27 standalone performance highlights, showing revenue from operations at ₹756.3 Cr, a 37.1% YoY increase, with EBITDA at ₹111.7 Cr and PAT at ₹64.5 Cr, representing 60.7% and 89.9% YoY growth respectively.
IOL Chemicals and Pharmaceuticals Limited
IOL Chemicals and Pharmaceuticals Limited has submitted the newspaper publication of un-audited Financial Results for the quarter ended 30th June 2026 to the National Stock Exchange of India Ltd.
IOL Chemicals and Pharmaceuticals Limited
IOL Chemicals and Pharmaceuticals Limited has announced its Q1 FY27 results, reporting a record quarterly performance with highest-ever revenue, driven by improved capacity utilisation, favourable product mix and operational efficiencies. The company's Pharmaceuticals business saw a 43% YoY revenue growth and 72% YoY EBIT growth, while the Chemicals business delivered 29% YoY revenue growth and 193% YoY EBIT growth.
IOL Chemicals and Pharmaceuticals Limited
IOL Chemicals and Pharmaceuticals Limited has submitted its unaudited financial results for the quarter ended June 30, 2026, which show a profit before exceptional items and tax of ₹86.77 crore.
IOL Chemicals and Pharmaceuticals Limited
IOL Chemicals and Pharmaceuticals Limited has informed the Exchange about the publication of the Notice of the 39th Annual General Meeting and e-voting information in newspapers, as well as the availability of the AGM Notice and Integrated Annual Report on the company's website and the website of Central Depository Services (India) Limited.
IOL Chemicals and Pharmaceuticals Limited
IOL Chemicals and Pharmaceuticals Limited has informed the Exchange about the schedule of an analyst/investor conference call to discuss the financial performance of the Company for the quarter ended 30th June 2026.
IOL Chemicals and Pharmaceuticals Limited
IOL Chemicals and Pharmaceuticals Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 02, 2026.
IOL Chemicals and Pharmaceuticals Limited
IOL Chemicals and Pharmaceuticals Limited has informed the Exchange about the publication of a newspaper advertisement for its 39th Annual General Meeting, which will be held through Video Conferencing on September 2, 2026.
IOL Chemicals and Pharmaceuticals Limited
IOL Chemicals and Pharmaceuticals Limited has received approval from the National Medical Products Administration (NMPA), China for its API product 'Clopidogrel Bisulfate'. This approval is in addition to the existing Certificate of Suitability (CEP) held by the company, strengthening its regulatory portfolio and expanding its access to the Chinese pharmaceutical market.
IOL Chemicals and Pharmaceuticals Limited
IOL Chemicals and Pharmaceuticals Limited has submitted a certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming the dematerialization of physical share certificates and substitution of the depository's name as the registered owner.
IOL Chemicals and Pharmaceuticals Limited
IOL Chemicals and Pharmaceuticals Limited has informed the Exchange about the reaffirmation of its credit rating by CARE Ratings Limited.
IOL Chemicals and Pharmaceuticals Limited
IOL Chemicals and Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.
IOL Chemicals and Pharmaceuticals Limited
IOL Chemicals and Pharmaceuticals Limited announced the publication of newspaper notices concerning two key investor-focused initiatives. These initiatives include a "Special Window for Transfer-cum-Dematerialisation of Physical Shares" and IEFP’s ‘Saksham Niveshak’ campaign. The primary objective is to facilitate shareholders in claiming unpaid or unclaimed dividends and updating their Know Your Customer (KYC) details. This announcement is significant for investors holding physical shares or those with outstanding dues, providing a crucial opportunity to regularize their holdings and ensure compliance.